Hyloris' Maxigesic IV receives FDA approval for pain management
Hyloris Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for new drug application (NDA) for Maxigesic IV to manage pain.
📰 Van Rompay News
Page 2 - Van Rompay News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Van Rompay. Real-time updates on events, politics, business and more.
Hyloris shareholders approve all resolutions at the Annual
56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated...
Jean Luc Vandebroek Stijn Van Rompay Sven Watthy Hyloris Pharmaceuticals Investor Relations Communications Hyloris Pharmaceuticals Sa Euronext Brussels
Source: globenewswire.com
Hyloris shareholders approve all resolutions at the Annual General Meeting
56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated Information – Inside Information -... | June 13, 2023
Sven Watthy Jean Luc Vandebroek Stijn Van Rompay Hyloris Pharmaceuticals Hyloris Pharmaceuticals Sa Euronext Brussels Investor Relations Communications
Source: marketscreener.com
Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region
Regulated Information - Liège, Belgium – 08 June 2023 – 6 PM CET – Hyloris Pharmaceuticals SA , a specialty biopharma company committed to addressing unmet medical... | June 8, 2023
Source: marketscreener.com
Hyloris announces submission of Maxigesic® IV packaging
Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological...
United States Sven Watthy Stijn Van Rompay Jean Luc Vandebroek Hyloris Pharmaceuticals Sa Euronext Brussels Hyloris Pharmaceuticals
Source: globenewswire.com
Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for... | April 18, 2023
United States Stijn Van Rompay Sven Watthy Jean Luc Vandebroek Hyloris Pharmaceuticals Investor Relations Communications
Source: marketscreener.com
Mithra Pharmaceuticals S A : announces the appointment of David H Solomon as Chief Executive Officer
Liege, Belgium, 4 April 2023 - 7:00 CET - Mithra , a company dedicated to Womens Health, appoints Dr. David H Solomon as Chief Executive Officer starting on April 11th, 2023. This follows the... | April 4, 2023
Source: marketscreener.com
AFT, Salus sign agreement for pain treatment Maxigesic IV
AFT Pharmaceuticals and Salus Pharmaceuticals have signed an exclusive licensing and distribution agreement for Maxigesic IV.
Hyloris Announces Commercial Partnership for Maxigesic® IV
Exclusive licensing and distribution agreement signed with Salus Pharmaceuticals in Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia,...
Sven Watthy Pharma Gmb Stijn Van Rompay Jean Luc Vandebroek November Maxigesic Hyloris Pharmaceuticals Sa Euronext Brussels
Source: globenewswire.com
Hyloris signs distribution deal with Slovenia's Salus
Belgian specialty biopharma company Hyloris has signed an exclusive licensing and distribution agreement with Slovenian pharmaceutical products wholesaler
Source: seenews.com